Literature DB >> 26313131

Simultaneous quantitation of quetiapine and its active metabolite norquetiapine in rat plasma and brain tissue by high performance liquid chromatography/electrospray ionization tandem mass spectrometry (LC-MS/MS).

Xiangkun Yang1, Indrani Poddar2, Caterina M Hernandez2, Alvin V Terry2, Michael G Bartlett3.   

Abstract

A sensitive method to simultaneously quantitate quetiapine and norquetiapine in rat plasma and brain tissue was developed using a one-step liquid-liquid extraction for sample preparation and LC-MS/MS for detection. The method provided a linear range of 1.0-500.0ng/mL for each analyte in plasma and 3.0-1500.0ng/g in brain tissue. The method was validated with precision within 15% relative standard deviation (RSD), accuracy within 15% relative error (RE), matrix effects within 10% and a consistent recovery. This method has been successfully applied in a preclinical study of quetiapine and norquetiapine to simultaneously determine their concentrations in rat plasma and brain tissue.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain; LC-MS/MS; Norquetiapine; Plasma; Quetiapine

Mesh:

Substances:

Year:  2015        PMID: 26313131     DOI: 10.1016/j.jchromb.2015.08.011

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  3 in total

1.  Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine.

Authors:  Indrani Poddar; Patrick M Callahan; Caterina M Hernandez; Xiangkun Yang; Michael G Bartlett; Alvin V Terry
Journal:  Biochem Pharmacol       Date:  2017-11-24       Impact factor: 5.858

2.  A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study.

Authors:  Xiujuan Chen; Chen Liang; Lijun Cui; Jian Le; Zheyuan Qian; Runsheng Zhang; Zhanying Hong; Yifeng Chai
Journal:  J Food Drug Anal       Date:  2018-08-14       Impact factor: 6.157

3.  Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent.

Authors:  Bassam M Ayoub; Shereen Mowaka; Marwa M Safar; Nermeen Ashoush; Mona G Arafa; Haidy E Michel; Mariam M Tadros; Mohamed M Elmazar; Shaker A Mousa
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.